77% of consumers who have used a GLP-1 were diagnosed as overweight or obese by a healthcare provider within the past five years
While not always separately quantified in clinical trial data, bloatingcharacterized by a sensation of abdominal fullness, distension, or tightnessis recognized as part of the broader spectrum of gastrointestinal side effects associated with GLP-1 receptor agonists
We ask that patients enter the office unaccompanied
So, for about half a century, theres been healthy skepticism about new-kid-on-the-block obesity drugs promising profound weight loss, only to see one after another fail and flop
Some may experience slight nausea or digestive changes as their body adjusts
5 Outcomes, stage for stage, are very similar for PTC and FTC